Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
1(16.7%)
Phase 3
1(16.7%)
6Total
Phase 1(4)
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03279146Phase 1Completed

A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects

Role: lead

NCT03284164Phase 1Completed

Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex

Role: lead

NCT02412917Phase 3Terminated

A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia

Role: lead

NCT02710604Phase 2Completed

Phase 2, Multiple Ascending Dose Proof of Concept Study

Role: lead

NCT02585440Phase 1Completed

A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects

Role: lead

NCT02322957Phase 1Completed

A Study Investigating the Pharmacokinetics of FV-100 With and Without Ritonavir in Healthy Volunteers

Role: lead

All 6 trials loaded